Search for Novel Diagnostic Biomarkers of Prostate Inflammation-Related Disorders: Role of Transglutaminase Isoforms As Potential Candidates

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2019 Jul 31

PMID 31360119

Authors

Maria Pia Savoca

Antonino Inferrera

Elisabetta A M Verderio

Daniela Caccamo

Affiliations

Soon will be listed here.

Abstract

Investigations on prostate inflammation-related disorders, including acute and chronic prostatitis, chronic pelvic pain syndrome, benign prostate hyperplasia (BPH), and prostate cancer (PCa), are still ongoing to find new, accurate, and noninvasive biomarkers for a differential diagnosis of those pathological conditions sharing some common macroscopic features. Moreover, an ideal biomarker should be useful for risk assessment of prostate inflammation progression to more severe disorders, like BPH or PCa, as well as for monitoring of treatment response and prognosis establishment in carcinoma cases. Recent literature evidence highlighted that changes in the expression of transglutaminases, enzymes that catalyze transamidation reactions leading to posttranslational modifications of soluble proteins, occur in prostate inflammation-related disorders. This review focuses on the role specifically played by transglutaminases 4 (TG4) and 2 (TG2) and suggests that both isoenzymes hold a potential to be included in the list of candidates as novel diagnostic biomarkers for the above-cited prostate pathological conditions.

References

Dubbink H, Hoedemaeker R, van der Kwast T, Schroder F, Romijn J . Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern. Lab Invest. 1999; 79(2):141-50. View

Rittmaster R, Thomas L, Wright A, Murray S, Carlson K, Douglas R . The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer. J Urol. 1999; 162(6):2165-9. DOI: 10.1016/S0022-5347(05)68153-0. View

An G, Meka C, Bright S, Veltri R . Human prostate-specific transglutaminase gene: promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer. Urology. 1999; 54(6):1105-11. DOI: 10.1016/s0090-4295(99)00298-8. View

Ponniah S, Arah I, Alexander R . PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate. 2000; 44(1):49-54. DOI: 10.1002/1097-0045(20000615)44:1<49::aid-pros7>3.0.co;2-7. View

Birckbichler P, Bonner R, Hurst R, Bane B, Pitha J, Hemstreet 3rd G . Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer. 2000; 89(2):412-23. DOI: 10.1002/1097-0142(20000715)89:2<412::aid-cncr29>3.0.co;2-o. View

Giri D, Ittmann M . Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol. 2001; 159(1):139-47. PMC: 1850405. DOI: 10.1016/S0002-9440(10)61681-1. View

Feldman B, Feldman D . The development of androgen-independent prostate cancer. Nat Rev Cancer. 2002; 1(1):34-45. DOI: 10.1038/35094009. View

Kramer G, Steiner G, Handisurya A, Stix U, Haitel A, Knerer B . Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate. 2002; 52(1):43-58. DOI: 10.1002/pros.10084. View

Griffin M, Casadio R, Bergamini C . Transglutaminases: nature's biological glues. Biochem J. 2002; 368(Pt 2):377-96. PMC: 1223021. DOI: 10.1042/BJ20021234. View

10.

Heuze-Vourch N, Leblond V, Courty Y . Complex alternative splicing of the hKLK3 gene coding for the tumor marker PSA (prostate-specific-antigen). Eur J Biochem. 2003; 270(4):706-14. DOI: 10.1046/j.1432-1033.2003.03425.x. View

11.

Steiner G, Newman M, Paikl D, Stix U, Memaran-Dagda N, Lee C . Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003; 56(3):171-82. DOI: 10.1002/pros.10238. View

12.

Nelson W, De Marzo A, Isaacs W . Prostate cancer. N Engl J Med. 2003; 349(4):366-81. DOI: 10.1056/NEJMra021562. View

13.

Lee S, Ku J, Park H, Jeong C, Kim S . Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis. J Urol. 2003; 170(3):745-8. DOI: 10.1097/01.ju.0000081650.23715.4c. View

14.

Steiner G, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F . Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003; 83(8):1131-46. DOI: 10.1097/01.lab.0000081388.40145.65. View

15.

Castro P, Xia C, Gomez L, Lamb D, Ittmann M . Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate. 2004; 60(2):153-9. DOI: 10.1002/pros.20051. View

16.

Quan G, Choi J, Lee D, Lee S . TGF-beta1 up-regulates transglutaminase two and fibronectin in dermal fibroblasts: a possible mechanism for the stabilization of tissue inflammation. Arch Dermatol Res. 2005; 297(2):84-90. DOI: 10.1007/s00403-005-0582-8. View

17.

Lewis T, Milam T, Klingler D, Rao P, Jaggi M, Smith D . Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer. Urol Oncol. 2005; 23(6):407-12. DOI: 10.1016/j.urolonc.2005.04.002. View

18.

Kramer G, Marberger M . Could inflammation be a key component in the progression of benign prostatic hyperplasia?. Curr Opin Urol. 2005; 16(1):25-9. View

19.

Blencowe B . Alternative splicing: new insights from global analyses. Cell. 2006; 126(1):37-47. DOI: 10.1016/j.cell.2006.06.023. View

20.

Penna G, Mondaini N, Amuchastegui S, Innocenti S, Carini M, Giubilei G . Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol. 2006; 51(2):524-33. DOI: 10.1016/j.eururo.2006.07.016. View